About

About Ritedose Corporation About Ritedose Corp The Ritedose Corporation is an industry leader in the CDMO, generic and 503B outsourcing markets. Founded in 1995 in Columbia, S.C., we use aseptic cGMP manufacturing and advanced blow-fill-seal (BFS) technology to ensure sterile, efficient and safe unit dose delivery. With its recent land acquisition, Ritedose operates entirely from a 130-acre campus in South Carolina. Ritedose has more than 575 employees and occupies 273,000 square feet of development, manufacturing and packaging space, driving an annual capacity of 2+ billion units. With the newly announced formation of Ritedose Performance Park and the buildout of an additional 225,000 sq ft Central Distribution Center, Ritedose will occupy over a half million sq ft under roof. Our highly touted, 27-year track record since 2012, includes delivery of more than 10 billion doses without a single interruption, and an exceptional inspection history and compliance record as noted by regulators, including the FDA. The Ritedose CDMO team shepherds products from early phase clinicals to commercial scale in an average 18 to 20 days from formulation to shipment and deploys rigorous environmental controls eliminating problems before they occur. The division produces both branded and generic solutions. Ritedose produces suspensions and emulsions for the inhalation, ophthalmic, otic and oral markets. Ritedose Pharmaceuticals provides an uninterrupted, reliable supply chain of unit dose generic inhalation medication for wholesalers and major pharmacy chains across the U.S. Our competitive pricing, aseptic manufacturing platform and packaging innovations allow our partners to feel confident in the products they offer to service patients. Our 503B outsourcing division delivers on-demand, pre-filled critical care syringe products that save valuable time in the pharmacy for clinicians who are stretched thin. Our innovative packaging allows for extended product dating of up to 360 days at room temperature storage. Appropriate product labeling and reliable concentrations facilitate safe patient care reducing potential bedside errors. Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com The Ritedose Corporation is an industry leader in the CDMO, generic and 503B outsourcing markets. Founded in 1995 in Columbia, S.C., we use aseptic cGMP manufacturing and advanced blow-fill-seal (BFS) technology to ensure sterile, efficient and safe unit dose delivery. With its recent land acquisition, Ritedose operates entirely from a 130-acre campus in South Carolina. Ritedose has more than 575 employees and occupies 273,000 square feet of development, manufacturing and packaging space, driving an annual capacity of 2+ billion units. With the newly announced formation of Ritedose Performance Park and the buildout of an additional 225,000 sq ft Central Distribution Center, Ritedose will occupy over a half million sq ft under roof. Our highly touted, 27-year track record since 2012, includes delivery of more than 10 billion doses without a single interruption, and an exceptional inspection history and compliance record as noted by regulators, including the FDA. The Ritedose CDMO team shepherds products from early phase clinicals to commercial scale in an average 18 to 20 days from formulation to shipment and deploys rigorous environmental controls eliminating problems before they occur. The division produces both branded and generic solutions. Ritedose produces suspensions and emulsions for the inhalation, ophthalmic, otic and oral markets. Ritedose Pharmaceuticals provides an uninterrupted, reliable supply chain of unit dose generic inhalation medication for wholesalers and major pharmacy chains across the U.S. Our competitive pricing, aseptic manufacturing platform and packaging innovations allow our partners to feel confident in the products they offer to service patients. Our 503B outsourcing division delivers on-demand, pre-filled critical care syringe products that save valuable time in the pharmacy for clinicians who are stretched thin. Our innovative packaging allows for extended product dating of up to 360 days at room temperature storage. Appropriate product labeling and reliable concentrations facilitate safe patient care reducing potential bedside errors.